Neogen Corporation: stock overview

NEOGNASDAQHealthcare · In Vitro & In Vivo Diagnostic Substances

Price

$11.23

November 13, 2026Market cap $2.4B

DCF calculator

What Ploutos Investor adds for Neogen

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from FY2010
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Neogen had revenue of $884M over the last 12 months and a net loss of $56M. Revenue grew by 13.2% a year on average over the last 5 years. It has net debt of $1.4B. It pays no dividend.

From its SEC filings (latest fiscal year to May 31, 2026) and the price of November 13, 2026.

Its SEC filings
Market cap
$2.4B
218M shares
P/E
–
Revenue, 12 months
$884M
+13.2% a year over 5 years
Net margin
-6.4%
FY2025: -0.9%, above 54% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

FY2024–FY2026 fiscal years

-3.0% a year over 2 years

  • FY2026May 31, 202610-K
    Revenue$870M
  • FY2025May 31, 202510-K
    Revenue$895M
  • FY2024May 31, 202410-K
    Revenue$924M

Fiscal years in figures

NEOG's revenue, profit, cash flow and dividend with each year-end price, from FY2010 to FY2023, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $2.0B
$2.4B
Enterprise value 
$3.8B
P/E 
–
EV / EBIT 
–
EV / Revenue 
4.3
P/B 3-year median: 0.9
1.2
FCF yield 3-year median: -2.7%
2.0%
Earnings yield 3-year median: -0.4%
–

Profitability

Gross margin 
47.4%
Operating margin 
-0.8%
Net margin 3-year median: -1.0%
-6.4%
ROIC 
-0.2%
ROIC, 5-year average 
-3.1%
ROE 
-2.7%

Growth

Revenue, yearly change 
-2.7%
EPS, yearly change 
–
FCF, yearly change 
–
Revenue, average a year 
+13.2%

The yearly change compares FY2026 with FY2025.

Balance sheet

Cash 
$172M
Total debt 
$1.6B
Net debt 
$1.4B
Net debt / EBITDA 
12.7x
Interest cover 
-0.3x
Current ratio 
3.90

Balance sheet of August 31, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+0.4%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Gross margin

46.9%

Above 56% of the 141 companies in its industry, and 65% of all.

Operating margin

-2.5%

Above 51% of the 285 companies in its industry, and 30% of all.

Net margin

-0.9%

Above 54% of the 302 companies in its industry, and 31% of all.

ROE

-0.4%

Above 54% of the 267 companies in its industry, and 29% of all.

ROA

-0.2%

Above 55% of the 313 companies in its industry, and 31% of all.

Revenue growth

-2.7%

Above 26% of the 292 companies in its industry, and 21% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
NEOGEN CORP
CIK
711377
Exchange
NASDAQ
Industry (SIC)
2835 · In Vitro & In Vivo Diagnostic Substances
Fiscal year ends
May 31
Latest annual report
May 31, 2026
Reporting currency
USD
Shares
218M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Neogen's filings show?

These are Neogen's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about NEOG

Didn't find what you were looking for?

Ask us
What is NEOG's market cap?

Neogen Corporation's market cap is $2.4B, at a price of $11.23 on November 13, 2026 and 218M shares.

How much revenue does NEOG have?

Neogen had revenue of $884M over the last 12 months. Over the last 5 years it changed by +13.2% a year on average.

Does NEOG pay a dividend?

No. Neogen paid no regular dividend over the last 12 months.

Where do the figures come from?

From Neogen Corporation's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.